Patent classifications
G01N33/5695
COMPOSITIONS USEFUL IN THE DIAGNOSTIC OF LATENTLY INFECTED MYCOBACTERIUM TUBERCULOSIS
The present invention concerns a composition comprising at least three peptides derived from Mycobacterium tuberculosis antigen Rv2626c, its use in the diagnostic of latently infected Mycobacterium tuberculosis (LTBI) subjects, corresponding methods of use and kits.
METHOD AND KIT FOR DETECTION OF MYCOBACTERIA
A method of determining whether an individual is infected with mycobacteria. The method comprising the steps of (a) providing a system which comprises at least two different mycolic-acid derived antigens; (b) introducing a sample obtained from the individual into the system and into contact with each of the at least two different mycolic-acid derived antigens; and (c) detecting the presence or absence of the binding of a biomarker in the sample with each antigen in the system. The method may be particularly suitable for determining the presence or absence of a disease antibody indicative of infection with any disease caused by infection with mycobacteria, for example tuberculosis, leprosy, pulmonary disease, burili ulcer, Johne's disease and bovine tuberculosis. A kit and device are also described. The present invention may provide an over the counter device to allow individuals to check on a routine basis that they have normal immune responses.
MYCOBACTERIUM TUBERCULOSIS PROTEINS
The present invention relates to Mycobacterium tuberculosis (M tuberculosis) proteins and immunologically active fragments (peptides or mimotope peptides) thereof. In particular, the invention relates to a group of M. tuberculosis proteins and peptides thereof that are both highly antigenic and characteristic of clinical strains of M. tuberculosis. Accordingly, the further relates to the use of these M. tuberculosis proteins or peptides in diagnosing, treating or preventing M. tuberculosis complex infection.
Antibodies directed against signal peptides, methods and uses thereof
Provided are methods employing antibodies directed against the signal peptide (SP) domain of various disease-associated polypeptides. These anti-SP antibodies detect cell surface expression of these SP domains and are used in methods of diagnosis and/or therapy. Provided is a method for determining the suitability for treatment of a subject suffering from a disease, whereby detection of cell surface expression of a specific SP indicates that the subject would benefit from therapy directed against this SP. Further, provided are methods for diagnosis of diseases based on the detection of endogenously produced anti-SP antibodies.
Point of care assays to detect the status of tuberculosis infection
Point of care methods to detect the probability or status of tuberculosis infection in individuals by determining presence or absence of one or more peptide of SEQ ID NOS:1-22 in a biological fluid of a subject are described. These methods may be assays based on affinity reagents specifically reactive with these peptides.
Sample Collection and Analysis
Management of the health status of an animal colony using a plurality of blood collection cards and the analysis of dried blood from members of the colony that has been collected on the cards. Members of the colony may be removed from the colony as a result of the analysis.
Assays for antimicrobial activity and applications thereof
The disclosure provides methods, compositions, and kits for enhanced detection of microbes in samples and monitoring of antimicrobial activity in a subject.
Methods and kits for determining tuberculosis infection status
There is provided methods of determining tuberculosis (TB) infection status in an individual comprising: (i) providing a sample comprising T-cells; (ii) exposing the sample of (i) to one or more TB antigens; (iii) identifying T-cells in the sample that are CD4 positive and (a) secrete TNF-α without secreting IFN-γ; or (b) secrete IFN-γ without secreting TNF-α; (iv) identifying those cells of (iii) which are also CCR7 and, CD127 negative; and optionally (v) calculating the cells identified in (iv) as a percentage of those identified in (iii); wherein the identification of cells in (iv) and/or the percentage of T-cells calculated in (v) correlates to TB infection status of the individual, and wherein steps (iii) and (iv) can be carried out either sequentially or simultaneously. There are also provided compositions and kits for use in such methods.
Device and associated methods for performing luminescence and fluorescence measurements of a sample
Apparatuses and methods of optically analyzing fluid within a pipette are described herein. In an embodiment, an optical reader subassembly includes a pipette configured to aspirate and hold a fluid sample within its tip, a housing configured to receive at least the tip of the pipette through a reentrant seal so that the tip of the pipette is located in a light tight manner within an internal area, a light source positioned to be in proximity to the tip of the pipette when the tip of the pipette is received by the housing, the light source configured to project light through the tip of the pipette and onto the fluid sample held within the tip, and an optical sensor configured to take a reading of the fluid sample held within the tip of the pipette without any of the fluid sample being injected from the pipette.
METHODS AND COMPOUND FOR THE IDENTIFICATION AND TREATMENT OF TUBERCULOSIS
A method to diagnose bacterial infection, including phenotyping cell based resistant mycoplasm, amplification and identification of infection, and performing at least one assay on a cell culture.